<!DOCTYPE HTML>
<html>
  <head>
    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">
    <meta http-equiv="Content-type" content="text/html; charset=utf-8">
    <title>Duloxetine (Cymbalta)</title>

	</head>
  <body onLoad="init();">
    <div data-role="page" data-theme="b">
  	<div data-role="header" data-theme="b" data-position="fixed">
    	<h1>Duloxetine</h1> 
    	<a href="#" data-rel="back" data-icon="arrow-l" data-theme="b" data-direction="reverse" >Back</a>
	</div>
    <div data-role="content">
<h3>Brand name: Cymbalta</h3>
<hr>
					<h3>Adult Starting Dose (Max Per Day)</h3>	
					<ul>
						<li>Initial adult dose = 20mg to 30 BID</li>
						<li>Max dose/day = 60mg QD</li>
						<li>Initial geriatric dose/day = 10=20 mg BID</li>
					</ul>
<hr>
					<h3>Advantages</h3>	
					<ul>
						<li>May be taken without regard to meals</li>
						<li>Duloxetine approved for use in generalized anxiety disorder</li>
						<li>Do not chew, crush or open capsules</li>
					</ul>
<hr>
					<h3>Disadvantages</h3>	
					<ul>
						<li><b>Contraindications include hypersensitivity to escitalopram</b></li>
						<li>May increase BP</li>
						<li>Avoid in patients with substantial alcohol use or evidence of chronic liver disease</li>
						<li>Avoid if CRCL &lt; 30ml/min and in hepatic impairment</li>
					</ul>
<hr>
					<h3>Pregnancy Category</h3>	
					<ul>
						<li>In third trimester:</li>
						<ul>
							<li>Risk cannot be ruled out, but potential benefits may justify potential risk</li>
							<li>Positive evidence of risk; However potential benefits may outweigh potential risks</li>
						</ul>		
					</ul>
<hr>
					<h3>Safety Margin for SNRIs</h3>	
					<ul>
						<li>More lethal in overdose (with other drugs &amp; alcohol) than SSRIs but not as lethal as TCAs</li>
						<li>Contraindicated concomitant use with MAOIs within two weeks of therapy</li>
						<li>Duloxetine contraindicated with thioridazine</li>
						<li>Avoid concomitant use with sibutramine, cimetidine, alcohol, Triptans, tramadol, Serotonergic agents, valerian, st.john's wort, SAMe and kava kava</li>
						<li>Avoid concomitant use of venlafaxine with trifluoperazine or weight loss agents</li>
						<li>Avoid concomitant use of duloxetine with fluvoxamine or Quinolones</li>
						<li>Use with caution with either warfarin or NSAID with duloxetine</li>
						<li>Taper dose slowly to prevent clinically significant discontinuation symptoms</li>
					</ul>
<hr>
					<h3>Efficacy for SNRIs</h3>	
					<ul>
						<li>Response rate: mild depression = 4-8 weeks; Moderate depression = 8-12 week; Severe depression = augmentative strategies, concurrent administration of adjuncts (referral to specialist)</li> 
						<li>Efficacy of duloxetine for diabetic peripheral neuropathy has been established by two controlled studies where patients reported a 30% sustained reduction inpain</li> 
						<li>Duloxetine approved for use in diabetic peripheral neuropathy and fibromyalgia</li>
						<li>May consider in the management of PTSD</li>
					</ul>
<hr>
<a href="../adverse_effects.html" data-role="button">Adverse Effects</a>
    </div><!-- end jqm content -->
   
    </div><!-- end jqm page -->
  </body>
</html>
